Intensity Therapeutics Inc. (NASDAQ:INTS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has earned an average rating of “Moderate Buy” from the four ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $37.50.

INTS has been the subject of several research reports. Weiss Ratings lowered shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. Wall Street Zen upgraded shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Finally, Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th.

Hedge Funds Weigh In On Intensity Therapeutics

Several large investors have recently made changes to their positions in INTS. Mesirow Financial Investment Management Inc. boosted its position in shares of Intensity Therapeutics by 81.8% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 200,000 shares of the company’s stock valued at $49,000 after purchasing an additional 90,000 shares in the last quarter. Legacy Advisors LLC purchased a new stake in Intensity Therapeutics during the fourth quarter valued at about $63,000. Geode Capital Management LLC lifted its stake in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares in the last quarter. Jane Street Group LLC purchased a new stake in Intensity Therapeutics during the fourth quarter valued at about $26,000. Finally, State Street Corp lifted its stake in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares in the last quarter. Institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Stock Performance

Shares of INTS opened at $4.46 on Thursday. The firm has a 50-day moving average price of $5.35 and a 200 day moving average price of $8.08. The firm has a market capitalization of $12.04 million, a PE ratio of -0.78 and a beta of 2.94. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 52-week low of $4.46 and a 52-week high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. On average, sell-side analysts anticipate that Intensity Therapeutics will post -2.7 earnings per share for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.